Ozempic, Wegovy & Rybelsus Lawsuit: Justice for Serious GI Injuries

Home » drug injury » weight loss drug lawsuits » ozempic wegovy rybelsus lawsuit

People across the country who used GLP-1 medications like Ozempic, Wegovy, or Rybelsus for weight loss or diabetes management are now facing severe gastrointestinal (GI) complications they never expected. If you took one of these medications and developed gastroparesis, intestinal blockage, ileus, or other serious digestive problems, you may have the right to pursue compensation from the manufacturers who failed to adequately warn about these risks.

The legal battle is underway. Cases are consolidated in MDL 3094 in the Eastern District of Pennsylvania, and the litigation continues to evolve as the FDA updates warnings and courts issue rulings about evidence requirements.

At Ferrer Poirot Feller, we’re standing with individuals who trusted these heavily marketed medications, only to suffer debilitating complications that have disrupted their lives. Our attorneys are here to help you understand what these medications did to your body, why manufacturers should have warned you sooner, and how you can seek accountability.

Call Ferrer Poirot Feller today at (214) 521-4412 for a free, confidential case evaluation. You won’t pay anything unless we win your case.

Schedule a Free Consultation

Key Takeaways for Ozempic, Wegovy & Rybelsus Lawsuits

• Federal cases are consolidated in MDL 3094 in the Eastern District of Pennsylvania under Judge Karen S. Marston, focusing on gastrointestinal injuries from GLP-1 medications
• Alleged injuries include gastroparesis (stomach paralysis), ileus, intestinal obstruction, and severe gastrointestinal complications that have left many patients unable to eat normally or digest food properly
• The FDA has updated warnings for Ozempic to include ileus (intestinal blockage), and Wegovy and Rybelsus labels now include stronger gastrointestinal warnings
• Primary defendants are Novo Nordisk (maker of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (maker of Trulicity and Mounjaro), facing claims they failed to warn about serious GI risks
• Recent court orders emphasize objective testing requirements for gastroparesis claims, meaning documentation like gastric emptying studies strengthens cases

Why Hire Ferrer Poirot Feller for Your GLP-1 Drug Injury Claim

GLP-1 drugs were promoted as safe and effective solutions for weight loss and blood sugar control. But many users have experienced stomach paralysis, severe nausea and vomiting, intestinal obstructions, and other dangerous conditions that require ongoing medical care.

GLP-1 lawsuits present unique challenges because they involve complex medical causation, evolving FDA warnings, and strict documentation requirements. The court overseeing MDL 3094 has made clear that strong cases require objective medical testing to prove injuries. You need attorneys who understand these requirements and know how to build cases that meet them.

At Ferrer Poirot Feller, we’ve spent more than 35 years representing people harmed by pharmaceutical products that didn’t live up to their safety promises. We know how to work with gastroenterologists, radiologists, and medical experts who can review your diagnostic tests and establish the connection between GLP-1 use and your injuries.

You won’t face pharmaceutical company legal teams alone. We handle the legal aspects of your case, from gathering medical records to consulting with experts to filing in the MDL. You won’t pay us a dime unless we recover compensation for you.

Time matters in these cases. Evidence requirements are specific, and statutes of limitations vary by state. Call our weight loss drug lawsuit attorneys today at (214) 521-4412 for a free consultation.

What Injuries Are Alleged in Ozempic, Wegovy & Rybelsus Lawsuits?

The lawsuits filed by people affected by GLP-1 medications focus on several serious gastrointestinal injuries:

• Gastroparesis (stomach paralysis), a condition where the stomach loses its ability to properly move food into the small intestine, causing severe nausea, vomiting, malnutrition, and requiring long-term dietary changes or feeding tubes
• Ileus, a temporary but serious condition where intestinal motility stops, causing severe pain, bloating, inability to pass gas or stool, and sometimes requiring hospitalization
• Intestinal obstruction, including mechanical blockages and pseudo-obstruction where the intestines stop functioning without a physical blockage
• Severe and persistent nausea and vomiting, often requiring emergency room visits, IV fluids, and anti-nausea medications
• Cyclic vomiting syndrome, characterized by repeated episodes of severe vomiting with no apparent cause
• Malnutrition and severe weight loss, resulting from the inability to eat or digest food properly
• Dehydration and electrolyte imbalances, caused by persistent vomiting and inability to keep fluids down

Many of these conditions have required hospitalization, feeding tubes, surgical interventions, and permanent dietary restrictions. Some patients have been told their gastroparesis may never fully resolve, meaning they face a lifetime of digestive problems and medical management.

If you’ve experienced any of these complications after using Ozempic, Wegovy, or Rybelsus, our drug injury lawyers are here to help you understand your legal options.

What Is GLP-1 MDL 3094 and Where Is It?

Because hundreds of individual lawsuits were filed in federal courts across the country, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into a single proceeding. The GLP-1 medication cases are consolidated in MDL 3094 in the Eastern District of Pennsylvania under Judge Karen S. Marston.

The MDL focuses specifically on gastrointestinal injury claims related to GLP-1 drugs including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro. The court has issued multiple orders to manage the growing number of cases, including procedures for direct filing and requirements for the types of medical evidence needed to support claims.

What Does This Mean for Your Case?

MDL 3094 is not a class action. Each plaintiff maintains an individual claim with unique medical histories, medication use patterns, and injuries. However, pretrial work such as discovery, expert depositions, and legal arguments is handled collectively to make the process more efficient.

The court has emphasized that gastroparesis claims require objective testing, such as gastric emptying studies, rather than relying solely on symptom reports. This means strong cases need documentation showing delayed gastric emptying through recognized diagnostic procedures.

Bellwether trials are expected in the future. These test cases will help both sides evaluate the strength of claims and may lead to settlement negotiations.

Who Are the Defendants in GLP-1 Medication Lawsuits?

The lawsuits name pharmaceutical companies responsible for manufacturing and marketing GLP-1 medications without adequate warnings:

• Novo Nordisk, the maker of Ozempic (for type 2 diabetes), Wegovy (for weight loss), and Rybelsus (oral semaglutide for diabetes)
• Eli Lilly, the maker of Trulicity (dulaglutide) and Mounjaro (tirzepatide), which are also GLP-1 receptor agonists associated with similar gastrointestinal risks

These companies marketed their products heavily, particularly for weight loss, without fully disclosing the potential for severe and potentially permanent digestive complications. Advertising campaigns emphasized the benefits while downplaying or omitting information about serious gastrointestinal risks that emerged in clinical data and post-market surveillance.

Did the FDA Update Warnings for GLP-1 Medications?

Yes. The FDA has taken action in response to reports of serious gastrointestinal complications. In September 2023, the FDA updated the Ozempic label to include ileus (intestinal blockage) as a potential adverse reaction. The Wegovy and Rybelsus labels now include stronger warnings about gastrointestinal side effects, and the Rybelsus label specifically notes the medication is not recommended for patients with severe gastroparesis.

These label changes acknowledge what many patients had already experienced: GLP-1 medications carry risks of serious digestive complications that go beyond the typical nausea and upset stomach listed in earlier warnings.

However, for the millions of people who used these medications before the label updates, the warnings came too late. Many had already developed gastroparesis, ileus, or other serious conditions.

Do You Qualify for an Ozempic, Wegovy, or Rybelsus Lawsuit?

You don’t need every piece of documentation before reaching out to an attorney. You just need to know that you suffered serious digestive problems after using a GLP-1 medication. You may have a claim if:

• You used Ozempic, Wegovy, Rybelsus, Trulicity, or Mounjaro for diabetes management or weight loss
• You developed severe gastrointestinal problems during or after your treatment, including gastroparesis, ileus, intestinal obstruction, or persistent severe nausea and vomiting
• You have objective medical testing documenting your condition, such as gastric emptying studies, imaging showing delayed gastric emptying, or other diagnostic tests
• You required medical intervention, including hospitalization, medications to manage symptoms, dietary changes, or surgical procedures
• Your state’s statute of limitations hasn’t expired for your potential claim

At Ferrer Poirot Feller, we’ll work with you to gather your medical records, review your diagnostic tests, and evaluate whether you have a viable claim. Call us at (214) 521-4412 for a free case evaluation.

What Medical Records and Evidence Strengthen Your Claim?

Building a strong GLP-1 injury case requires documentation connecting your medication use to your gastrointestinal complications. Key evidence includes:

• Gastric emptying studies (also called gastric scintigraphy) showing delayed stomach emptying, which is the gold standard test for diagnosing gastroparesis
• Medical records documenting your GLP-1 prescription, dosage, duration of use, and the timeline of when symptoms began
• Emergency room records if you sought treatment for severe nausea, vomiting, dehydration, or intestinal blockage
• Hospitalization records, if you required inpatient treatment for GI complications
• Diagnostic imaging, such as upper GI series, CT scans, or MRIs, showing intestinal problems
• Endoscopy or colonoscopy results, if performed to evaluate your symptoms
• Pharmacy records showing when you filled prescriptions and how long you used the medication
• Documentation of treatments, including medications for nausea, dietary changes, or surgical interventions

If you experienced severe symptoms consistent with gastroparesis but haven’t undergone gastric emptying studies, talk to your healthcare provider about appropriate testing.

What Compensation Might Be Available?

If you pursue a successful GLP-1 injury claim, compensation might include:

• Medical expenses, including emergency room visits, hospitalizations, diagnostic tests, specialist consultations, and ongoing treatment
• Future medical care costs, such as continued gastroenterology care, medications, dietary supplements, or potential surgical interventions
• Lost income, if your gastrointestinal problems prevented you from working or required you to reduce hours
• Pain and suffering, reflecting the severe physical discomfort from persistent nausea, vomiting, and digestive dysfunction
• Emotional distress, acknowledging the psychological impact of chronic illness and dietary restrictions
• Loss of quality of life, including the inability to eat normally, participate in social activities involving food, or maintain your previous lifestyle
• Costs of dietary modifications, including special foods, nutritional supplements, or feeding equipment if required

The value of your case depends on the severity of your injuries, whether they’re permanent or temporary, the extent of medical treatment needed, and how the complications have affected your daily life.

What to Expect When Filing a GLP-1 Medication Injury Lawsuit

The legal process starts with a free consultation where we listen to your story, answer your questions, and explain your rights. If we believe you have a viable claim, here’s what the process might look like:

1. We collect your medical records, including documentation of your GLP-1 use, diagnostic test results, treatment records, and specialist evaluations
2. We document your medication timeline, establishing when you started the drug, what dosage you used, and when symptoms began
3. We consult with gastroenterology and pharmacology experts who can review your case and testify about the connection between GLP-1 use and your injuries
4. We file your claim in MDL 3094, joining others seeking justice from the same manufacturers
5. We handle the legal proceedings and communications, so you never have to deal with pharmaceutical company legal teams directly

Most mass tort cases settle before trial, but if your case needs to go to trial, we’re prepared. Throughout the process, our attorneys keep you informed about developments in your case and the broader litigation.

Latest GLP-1 MDL Updates and Timeline

MDL 3094 continues to evolve as more cases are filed and the court issues new orders. The judge has held regular status conferences to manage the litigation, establish discovery schedules, and set procedures for adding new cases.

Recent developments include:

• Direct filing procedures allowing attorneys to efficiently add cases to the MDL
• Emphasis on objective testing requirements for gastroparesis claims, with the court making clear that diagnostic evidence strengthens cases
• Discovery orders requiring defendants to produce documents about their knowledge of gastrointestinal risks and their marketing practices
• Expert witness deadlines as both sides prepare to present medical and scientific testimony

Bellwether trial schedules have not yet been finalized, but the litigation is progressing through pretrial phases. Settlement discussions may occur as discovery reveals more about what manufacturers knew and when they knew it.

If you’re considering filing a claim, don’t wait. Statutes of limitations vary by state, and gathering medical evidence becomes more difficult as time passes.

FAQ About Ozempic, Wegovy & Rybelsus Lawsuits

Contact Ferrer Poirot Feller for a Free Case Evaluation

If you developed gastroparesis, intestinal blockage, or other serious gastrointestinal problems after using Ozempic, Wegovy, Rybelsus, or other GLP-1 medications, you may have the right to hold the manufacturers accountable. We know how debilitating these digestive complications can be, and we’re here to help you seek justice.

At Ferrer Poirot Feller, we represent people across the country who’ve been harmed by pharmaceutical products they trusted. We offer free, no-obligation consultations, where you can speak directly with our team, ask questions, and gain a clear understanding of your legal options.

Call us today at (214) 521-4412 for your free case evaluation.

Schedule a Free Consultation

---

Ferrer Poirot Feller – Office

2603 Oak Lawn Ave #300,

Dallas, TX 75219

Phone: (214) 521-4655